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Abstract 
Introduction: We investigated whether increased concentrations of inspired oxygen (FiO2) 
affects exercise tolerance in patients with heart failure and normal ejection fraction 
(HeFNEF).  
Methods: 46 patients (mean age 75 years (63% male) and median NTproBNP 1432 
(interquartile range: 543-2378 ng/l)) with HeFNEF (defined as signs or symptoms of heart 
failure requiring treatment with diuretics, with a left ventricular ejection fraction of more than 
45% by echocardiography and amino terminal pro brain natriuretic peptide (NTproBNP) 
>220 ng/l) completed three maximal incremental exercise tests with different FiO2 (21%, 28% 
and 40%) in random order. FiO2 was controlled by investigator but blinded to patients. The 
primary outcome was exercise time (ET).  
Results: Increasing FiO2 significantly increased exercise time (522 ±180 seconds for 21% to 
543 ±176 seconds, and 542 ±177 seconds, for 28% and 40%, respectively, P=0.04) with no 
difference in peak workload (57 ±25 W, 58 ±25 W and 57 ±25 W, for 21%, 28% and 40%, 
respectively, P=0.50). There was an increase in oxygen saturation but no change in peak heart 
rate with increasing FiO2. Compared to patients with LVEF > 50%, patients with LVEF 
between 45 and 49% had a significantly greater exercise time and peak workload. There was 
a correlation between the difference in exercise time between FiO2 21% and 40% and age; but 
not with BMI, haemoglobin, creatinine or NTproBNP. 
Conclusion: Increasing FiO2 during exertion leads to a small increase in exercise time in 
patients with HeFNEF.  
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Introduction 
Epidemiological studies suggest that heart failure with normal ejection fraction (HeFNEF) 
accounts for almost 50% of patients with heart failure (HF), and its prevalence is 
increasing.
1,2,3
 Compared to patients with heart failure and reduced ejection fraction 
(HeFREF), those with HeFNEF are usually older and have more comorbidities,
4
 which plays 
a significant role in the development and/or worsening of HF symptoms and substantially 
contributes to the adverse prognosis of patients with HeFNEF. HeFNEF is a heterogeneous 
clinical syndrome which can be difficult to diagnose and treat.
4
  
Clinical trials have failed to demonstrate that any pharmacological treatment improves 
outcomes for patients with HeFNEF.
5,6,7,8,9,10
 However, another important aim of treatment is 
to alleviate symptoms and to improve wellbeing.
11
 The clinical hallmark of HeFNEF is 
exertional breathlessness, at least partially due to an abnormal increase in left atrial pressure 
during exercise.
4
 Reduction in delivery of oxygen to the periphery and myocardium might 
contribute to, and aggravate, breathlessness and fatigue.
4
 Small trials suggest that increasing 
inspired oxygen concentration during exercise might prolong exercise time and improve 
symptoms in patients with HeFREF or pulmonary hypertension,
12,13,14
 but the effect on 
patients with HeFNEF is unknown. 
We aimed to assess the effects of increasing inspired oxygen fraction (FiO2) on exercise 
capacity in patients with HeFNEF. 
 
Methods 
This was a single centre, randomised , single-blinded, cross-over trial in patients with 
HeFNEF. The research conforms to the Helsinki declaration. Ethics approval was granted by 
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an external research ethics committee. The trial was registered on the ClinicalTrials.gov 
website (Identifier: NCT02949531). All patients gave written informed consent. 
Ambulatory patients older than 50 years of age attending a community heart failure clinic 
were considered for the study if they had had a clinical diagnosis of heart failure with a left 
ventricular ejection fraction (LVEF) by echocardiography > 45% and a plasma concentration 
of amino terminal pro B type natriuretic peptide (NTproBNP) > 220 ng/l.
15
 Patients had to be 
taking a diuretic. Patients unable to exercise, and those who had severe mitral or aortic valve 
disease, haemoglobin < 100 g/l, estimated glomerular filtration rate <30 ml/min/1.73m
2
), or 
severe chronic obstructive pulmonary disease (FEV1 less than 50% predicted) were excluded 
from the study.  
 
Exercise protocol 
Patients undertook three maximal incremental exercise tests on a stationary cycle using a 
standardised exercise protocol. Patients cycled at 60 revolutions per minute starting from 0 
watts for 4 minutes; subsequently, resistance increased by 10 watts/minute. Patients were 
encouraged to exercise to their maximum capacity. At the end of the exercise test, the reason 
for stopping and modified Borg score were recorded.  
Inspired oxygen fraction (FiO2) was administered at different concentrations (21%, 28% and 
40%) in a random sequence which was computer generated. All three oxygen concentrations 
were delivered via a Venturi mask. This allowed the investigator to control the oxygen 
concentration administered whilst the patients and the technicians conducting the test were 
blinded to FiO2. During the exercise test, blood pressure, oxygen saturation, heart rate and 
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rhythm were continuously monitored. The three exercise tests were conducted at 
approximately weekly intervals.  
The primary endpoint was exercise time (ET; seconds). Secondary end points included: peak 
workload (watts), modified Borg score, peak heart rate (beats per minute), and peak arterial 
oxygen saturation (O2 sat; percentage).  
 
Statistical analysis 
Categorical data are presented as number and percentages; normally distributed continuous 
data as mean ± standard deviation (SD) and non-normally distributed continuous variables as 
median and interquartile range.   
Between-group means of the primary and secondary endpoints were compared using analysis 
of variance (ANOVA). The method uses ‘least squares’ to fit linear models. We used one-
way ANOVA with repeated measures on dose-group. An underlying assumption of the F test 
is independence of observations. In a repeated measures design, this assumption is almost 
certainly violated (observations from the same subject are likely to be correlated). To 
overcome this, we used a correction factor (a number have been proposed in the literature) to 
the degrees-of-freedom for the F test. We chose one developed by Box which is conservative 
in a statistical sense (if significant by Box it will be significant by the rest).
16
 Other 
assumptions of ANOVA were met. Paired t-tests were then used to compare the primary and 
secondary endpoints between exercise tests.  
Sub-group analysis of the primary and secondary endpoints were pre-specified  and used to 
explore the relation between age, haemoglobin, creatinine, NTproBNP, body mass index 
(BMI), sex, the use of a walking aid and heart rhythm (atrial fibrillation vs sinus rhythm) and 
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the end points. The current European Society of Cardiology guidelines on heart failure set an 
LVEF cut-off at 50% for diagnosing HeFNEF, so we re-analysed the results for patients 
above and below this LVEF cut-off.
11
 Primary and secondary endpoints are shown in 
boxplots. All analyses were performed on SPSS (V 23.0) and Stata statistical computer 
packages. A statistical significance was assumed at P<0.05 (two tailed). 
There were no missing values for exercise time so an analysis of missing data by multiple 
imputations was unnecessary.
17
 
 
Results 
Of the 50 patients enrolled, 46 patients completed the three visits, and 4 withdrew. 
(Supplementary Figure 1).The baseline characteristics of the 46 patients who completed the 
study are shown in table 1. Most patients were men, overweight and had NYHA class II 
symptoms. Compared to patients with LVEF > 50%, patients with LVEF between 45 and 
49% had a significantly higher NTproBNP and creatinine, and a lower haemoglobin. 
Increasing FiO2 led to an increase in exercise time of approximately 20 seconds (P=0.04). 
There was no dose response relation: exercise time was increased by the same amount during 
both tests with increased FiO2 compared with 21% FiO2. (Supplementary Table 1; Figure 1) 
Increasing FiO2 had no effect peak workload (P=0.50) and modified Borg score (P=0.17). 
(Supplementary Table 1; Figure 1) There was no effect of increasing FiO2 on heart rate during 
exercise (P=0.65), although arterial oxygen saturation throughout exercise was higher with 
increasing FiO2 (P=0.03). (Supplementary Table 1)   
Patients with LVEF > 50% had a lower exercise time and peak workload than those with 
LVEF between 45-49%, but had a slightly greater increase in exercise time with the increase 
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in FiO2 from 21% to 28%. (Table 2) There was no interaction between increasing FiO2 and 
exercise capacity in any subgroup. (Supplementary Table 2) There was a positive correlation 
between the difference in exercise time between FiO2 of 21% and 40% and age, but not with 
BMI, haemoglobin, creatinine or NTproBNP level. (Supplementary Table 3) 
 
Discussion 
We have found that in patients with HeFNEF, increasing oxygen concentration during 
exercise lead to a small increase in exercise time but had no effect on peak work load.   
There are no previous trials of supplementary oxygen during exercise in patients with 
HeFNEF. Trials of oxygen supplementation during exercise in patients with heart failure with 
reduced ejection fraction (HeFREF) have yielded mixed results. Moore and colleagues 
reported a dose dependent increase in exercise time from 548 ±275 seconds on room air to 
632 ±288 seconds with FiO2 of 50% in 12 patients with HeFREF during resistance cycling on 
a stationary bike to maximum capacity (workload was increased by 15 W at 2-min 
intervals).
12
 In contrast, Russell and colleagues found no effect of increasing FiO2 to 60% on 
exercise time compared to 21% FiO2 during symptom limiting resistance cycling on a 
stationary bike (2-minute resting period followed by increasing workloads of 25 W every 3 
minutes) in 16 patients with LVEF <35%.
18
 Restrick found no effect of oxygen delivered at 4 
l/min on 6 minute walk test distance in 12 patients with stable chronic heart failure.
19
 We 
studied 31 patients with HeFREF (mean LVEF 31%) and found that exercise time, maximal 
workload and maximal metabolic equivalent all increased significantly with increasing FiO2 
from 21%, to 28% and 40% FiO2.
13
 In a study of 22 patients with pulmonary hypertension 
(pulmonary arterial or chronic thrombo-embolic pulmonary hypertension), increasing FiO2 to 
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50% approximately doubled exercise time (from 571 ± 443seconds to 1242 ± 514 seconds) 
and maximal work rate (113 ± 38 W to 132 ± 48 W).14  
Why should increased FiO2 improve exercise performance in patients with HeFREF, but not 
make a substantial difference in those with HeFNEF? Part of the explanation may be that 
HeFNEF is something of a diagnostic rag-bag. Extra-cardiac mechanisms may significantly 
contribute to impaired exercise tolerance in patients with HeFNEF. Those with HeFNEF tend 
to be older than those with HeFREF, are more likely to be overweight or obese and have 
chronic lung problems (and other comorbidities including anaemia).
20,21
 Sarcopenia and loss 
of muscle bulk are common in older people and particularly in patients with HeFNEF.
22
 
Patients with HeFNEF are thus, perhaps, more likely to have conditions other than their heart 
failure that limits exercise, and hence oxygen is less likely to help their exercise performance.   
In the present study, overall we found no relation between cardiac rhythm or plasma 
NTproBNP and exercise time. We found, perhaps paradoxically, that patients with LVEF 
between 45-49% had a longer ET than those with higher LVEF (>50%), despite having a 
significantly greater plasma NTproBNP and lower haemoglobin level. Patients with LVEF 
between 45-49% may represent patients who truly have lower exercise capacity due to heart 
failure rather than those with LVEF >50% whose exercise performance might not be entirely 
related to the heart.
23
 
The mechanisms causing exercise intolerance in patients with heart failure are complex.
24
 In 
most stable ambulatory patients with HeFREF, haemodynamics at rest are not substantially 
impaired.
25
 Major determinants of exercise capacity appear to lie in the periphery, with 
abnormal skeletal muscle performance being chiefly implicated. The situation may be 
different in patients with HeFNEF: again, haemodynamics at rest may be normal, but during 
exercise, there is a disproportionate increase in left atrial pressure,
26 
which contributes to 
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symptoms and is associated with worse long term outcomes.
27
 Trials in patients with 
HeFNEF which have exercise capacity as a primary endpoint may be likely to fail due to the 
heterogeneity of the condition.   
 
Limitations 
We only enrolled patients able to exercise. We also only included patients treated with a 
diuretic; this might have led to a population of patients with HeFNEF with a more severe 
disease profile.
28
 Monitoring central haemodynamics during exercise testing might have 
added to the understanding of the causes of exercise intolerance in patients with HeFNEF.  
We included some patients who had an LVEF 45% - 49% on echocardiography. According to 
the current ESC HF guidelines, these patients would fall into the newly introduced category 
of “heart failure with mid-range ejection fraction” (HFmrEF).11 Such patients might represent 
a separate phenotype from patients with HeFNEF.  
 
Conclusions 
Increasing FiO2 during exertion leads to a small increase in exercise time in patients with 
HeFNEF which is unlikely to be clinically significant. 
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Baseline characteristics of patients who completed the study 
Baseline characteristics 
 
All patients 
(N = 46) 
LVEF > 50% 
(N= 29) 
LVEF 45-49% 
(N= 17) 
Demographics 
Age (yrs) 75 (8) 76 (8) 75 (8) 
Male Sex (%) 29 (63) 18 (62) 11 (65) 
SBP (mmHg) 146 (23) 150 (23) 140 (23) 
Heart rate (bpm) 69 (11) 70 (11) 68 (11) 
BMI (kg/m
2
) 31 (7) 32 (8) 31 (6) 
Weight (kg) 90 (25) 91 (28) 91 (18) 
NYHA function class 
I (%) 4 (9) 3 (10) 1 (6) 
II (%) 37 (80) 23 (79) 14 (82) 
III (%) 5 (11) 3 (10) 2 (12) 
Medical history 
Hypertension (%) 28 (61) 19 (66) 9 (53) 
Diabetes (%) 16 (35) 10 (35) 6 (35) 
IHD (%) 20 (44) 13 (45) 7 (41) 
Stroke (%) 3 (7) 3 (10) 0 (0) 
#Asthma/ COPD (%) 10 (22) 8 (28) 2 (12) 
Walking aids (%) 14 (30) 9 (31) 5 (29) 
Blood test 
NTproBNP (ng/l) 
1432         
(543 – 2378) 
1282         
(443 – 2244) 
2184          
(1372 – 2501)* 
Hb (g/l) 12.9 (1.7) 13.5 (1.7) 12.0 (1.5)* 
Creatinine (µmol/l) 102 (80 – 137) 98 (75 – 125) 125 (95 – 155)* 
ECG and ECHO 
Sinus rhythm (%) 21 (46) 15 (52) 6 (35) 
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Mean LVEF (%) 54 (7) 58 (5) 47 (1)* 
LA size (cm) 4.3 (0.6) 4.2 (0.6) 4.5 (0.5) 
IVS (cm) 1.1 (0.2) 1.1 (0.2) 1.1 (0.2) 
Spirometry 
FCV % predicted 70 (17) 69 (21) 71 (12) 
FEV1 % predicted 75 (20) 77 (23) 73 (17) 
Medical therapy 
Beta blocker (%) 37 (80) 23 (79) 14 (82) 
ACEi (%) 30 (65) 17 (59) 13 (77) 
ARB (%) 10 (22) 7 (24) 3 (18) 
Loop diuretics (%) 39 (89) 26 (90) 13 (77) 
MRA (%) 23 (50) 13 (45) 10 (59) 
Diuretic (%) 46 (100) 29 (100) 17 (100) 
Digoxin (%) 8 (17) 8 (28) 0 (0)* 
Statin (%) 34 (74) 22 (76) 12 (71) 
Aspirin (%) 14 (30) 10 (35) 4 (24) 
Anticoagulant (%) 28 (61) 16 (55) 12 (71) 
Table 1: Baseline characteristics for all patients who completed three visits of the study and divided 
according to LVEF (> 50% or between 45-49%). SBP: systolic blood pressure, BMI: body mass 
index; NYHA: New York Hear Association, IHD: ischaemic heart disease, COPD: chronic 
obstructive pulmonary disease, NTproBNP: Amino terminal pro brain natriuretic peptide, Hb: 
haemoglobin, ECG: electrocardiogram, ECHO: echocardiography, LVEF: left ventricular ejection 
fraction, LA: left atrial; IVS: interventricular septum, FCV: forced vital capacity, FEV1: forced 
expiratory volume in 1 second, ACEi: Angiotensin converting enzyme inhibitor, ARB: angiotensin 
receptor blocker, MRA: mineralocorticoid receptor antagonist. Categorical variables are expressed as 
number (percentage) and continuous variables are expressed as mean (standard deviation) or median 
(interquartile range) depending on distribution. P values significant (<0.05) between LVEF > 50% 
and 45-49%. # those with severe COPD (FEV1 less than 50% predicted) were excluded from the 
study. 
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Differences in the endpoint variables between LVEF > 50% and LVEF between 45-49% 
Variable LVEF 21% FiO2 28% FiO2 40% FiO2 
Mean exercise 
time (seconds) 
LVEF >50 482 (168) 509 (158) 504 (170) 
LVEF 45-49% 592 (184) 600 (194) 607 (173) 
P value  0.04 0.09 0.05 
Peak workload 
(watts) 
LVEF >50 50 (19) 54 (19) 53 (20) 
LVEF 45-49% 68 (31) 65 (32) 66 (30) 
P value  0.02 0.15 0.10 
modified Borg 
score 
LVEF >50 4.4 (1.9) 3.9 (1.4) 4.3 (2.0) 
LVEF 45-49% 4.6 (1.4) 4.7 (1.6) 4.7 (1.8) 
P value  0.66 0.07 0.55 
Peak heart rate 
(bpm) 
LVEF >50 101 (18) 103 (18) 101 (23) 
LVEF 45-49% 110 (36) 110 (26) 111 (30) 
P value  0.25 0.26 0.20 
Peak oxygen 
saturations (%) 
LVEF >50 96 (3) 97 (3) 98 (3) 
LVEF 45-49% 96 (5) 98 (3) 98 (3) 
P value  0.25 0.52 0.93 
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Table 2: Changes in primary and secondary endpoints with the use of supplementary oxygen 
in patients with LVEF >50% or LVEF between 45-49%. FiO2: concentration of inspired 
oxygen, LVEF: Left ventricular ejection fraction, bpm: beats per minute.  
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Highlights 
1. The clinical hallmark of heart failure with normal ejection fraction (HeFNEF) is 
breathlessness 
2. Increasing oxygen supplementation during exertion leads to a small increase in 
exercise time. 
3. However this is unlikely to be clinically significant in patients with HeFNEF. 
4. The mechanisms causing exercise intolerance in patients with HeFNEF are complex. 
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Figure Legends 
Figure 1: Increasing FiO2 resulted in a small increased mean exercise time without a 
significant difference found between 28% and 40% as presented by arrows, but no 
significantly change mean peak workload and mean modified Borg score 
Supplementary Figure 1: Total number of patients consented and completed all three visits 
of the study 
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